John Hofmann Pontius - Net Worth and Insider Trading
John Hofmann Pontius Net Worth
The estimated net worth of John Hofmann Pontius is at least $717 dollars as of 2024-05-05. John Hofmann Pontius is the Director of Oncternal Therapeutics Inc and owns about 82 shares of Oncternal Therapeutics Inc (ONCT) stock worth over $717. Details can be seen in John Hofmann Pontius's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John Hofmann Pontius has not made any transactions after 2005-02-24 and currently still holds the listed stock(s).
Transaction Summary of John Hofmann Pontius
John Hofmann Pontius Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John Hofmann Pontius owns 1 companies in total, including Oncternal Therapeutics Inc (ONCT) .
Click here to see the complete history of John Hofmann Pontius’s form 4 insider trades.
Insider Ownership Summary of John Hofmann Pontius
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ONCT | Oncternal Therapeutics Inc | 2005-02-24 | director |
John Hofmann Pontius Latest Holdings Summary
John Hofmann Pontius currently owns a total of 1 stock. John Hofmann Pontius owns 82 shares of Oncternal Therapeutics Inc (ONCT) as of February 24, 2005, with a value of $717.
Latest Holdings of John Hofmann Pontius
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ONCT | Oncternal Therapeutics Inc | 2005-02-24 | 82 | 8.75 | 717 |
Holding Weightings of John Hofmann Pontius
John Hofmann Pontius Form 4 Trading Tracker
According to the SEC Form 4 filings, John Hofmann Pontius has made a total of 0 transactions in Oncternal Therapeutics Inc (ONCT) over the past 5 years. The most-recent trade in Oncternal Therapeutics Inc is the acquisition of 1 shares on February 24, 2005, which cost John Hofmann Pontius around $10,700.
Insider Trading History of John Hofmann Pontius
- 1
John Hofmann Pontius Trading Performance
GuruFocus tracks the stock performance after each of John Hofmann Pontius's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Hofmann Pontius is 6.94%. GuruFocus also compares John Hofmann Pontius's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Hofmann Pontius within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John Hofmann Pontius's insider trading performs compared to the benchmark.
Performance of John Hofmann Pontius
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 8.3 | | | | | |
| Relative Return to S&P 500(%) | 7.45 | | | | | |
John Hofmann Pontius Ownership Network
John Hofmann Pontius Owned Company Details
What does Oncternal Therapeutics Inc do?
Who are the key executives at Oncternal Therapeutics Inc?
John Hofmann Pontius is the director of Oncternal Therapeutics Inc. Other key executives at Oncternal Therapeutics Inc include director & Executive Chairman Robert James Wills , Chief Scientific Officer Gunnar F. Kaufmann , and Chief Medical Officer Salim Yazji .
Oncternal Therapeutics Inc (ONCT) Insider Trades Summary
Over the past 18 months, John Hofmann Pontius made no insider transaction in Oncternal Therapeutics Inc (ONCT). Other recent insider transactions involving Oncternal Therapeutics Inc (ONCT) include a net purchase of 9,020 shares made by Robert James Wills , a net purchase of 150,000 shares made by James B Breitmeyer , and a net purchase of 30,000 shares made by Richard G Vincent .
In summary, during the past 3 months, insiders sold 980 shares of Oncternal Therapeutics Inc (ONCT) in total and bought 10,980 shares, with a net purchase of 10,000 shares. During the past 18 months, 980 shares of Oncternal Therapeutics Inc (ONCT) were sold and 23,880 shares were bought by its insiders, resulting in a net purchase of 22,900 shares.
Oncternal Therapeutics Inc (ONCT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Oncternal Therapeutics Inc Insider Transactions
John Hofmann Pontius Mailing Address
Above is the net worth, insider trading, and ownership report for John Hofmann Pontius. You might contact John Hofmann Pontius via mailing address: 175 Toyota Plaza, 7th Floor, Memphis Tn 38103.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
